EHAVE, Inc. (EHVVF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $2.37M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerEHAVE, Inc. (EHVVF) trades at $0.0016. EHAVE, Inc. is a healthcare technology company focused on developing medical psychedelics and a mental health data platform. Market cap: $2.37M, Sector: Technology.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for EHVVF: EHVVF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EHVVF against Technology peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
EHVVF: the 2 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
EHAVE, Inc. (EHVVF) Technology Profile & Competitive Position
EHAVE, Inc. develops medical psychedelics and a mental health data platform, integrating proprietary and third-party digital applications. Targeting clinicians, patients, and researchers, the company offers tools like MegaTeam and Ehave Dashboard. Based in Miami, Florida, EHAVE aims to enhance mental healthcare through data-driven insights and blockchain technology.
What Is the Investment Thesis for EHVVF?
EHAVE, Inc. presents a speculative investment opportunity within the emerging medical psychedelics and mental health technology sector. The company's focus on developing a comprehensive mental health data platform, integrating digital applications, and utilizing blockchain technology positions it to capitalize on the growing demand for innovative mental healthcare solutions. However, with a market capitalization of $2.37M and negative P/E ratio of -0.17, the company's financial performance and valuation require careful consideration. Key growth catalysts include the expansion of its product offerings, strategic partnerships with healthcare providers and pharmaceutical companies, and regulatory advancements in the medical psychedelics space. The company's ability to successfully commercialize its technology solutions and achieve profitability will be critical in driving long-term shareholder value. The negative beta of -0.19 suggests the stock moves contrary to the market, which may offer diversification benefits but also reflects potential investor uncertainty.
Based on FMP financials and quantitative analysis
EHVVF Key Highlights
EHAVE, Inc. operates in the healthcare technology sector, focusing on medical psychedelics and mental health data platforms.
- The company's key products include MegaTeam, Ninja Reflex, and Ehave Dashboard, offering digital assessment and rehabilitation tools.
- EHAVE's mental health informatics platform utilizes blockchain technology to provide data-driven insights for clinicians.
- The company targets clinicians, patients, researchers, pharmaceutical companies, and payors with its technology solutions.
- EHAVE, Inc. has a market capitalization of $2.37M and a negative P/E ratio of -0.17, reflecting its early-stage growth profile.
Who Are EHVVF's Competitors?
EHVVF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MNDO MIND C.T.I. Ltd. | $1.02 | +3.00% | $20.9M | 795-pillar |
| IDN Intellicheck, Inc. | $2.62 | +0.77% | $53.1M | 765-pillar |
| WFCF Where Food Comes From, Inc. | $13.20 | +3.94% | $66.5M | 725-pillar |
| TRAK ReposiTrak, Inc. | $7.89 | +0.25% | $143M | 785-pillar |
| PERF Perfect Corp. | $1.93 | +0.52% | $197M | 865-pillar |
| IMMR Immersion Corporation | $7.36 | -1.08% | $244M | 785-pillar |
| RMNI Rimini Street, Inc. | $4.58 | +0.11% | $427M | 775-pillar |
| MTLS Materialise NV | $7.64 | +2.83% | $447M | 755-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EHVVF's Key Strengths?
Proprietary mental health data platform and digital applications.
- Focus on integrating medical psychedelics and blockchain technology.
- Strategic partnerships with healthcare providers and pharmaceutical companies.
- Experienced management team with expertise in healthcare and technology.
What Are EHVVF's Weaknesses?
Limited financial resources and operating history.
- Dependence on regulatory approvals for medical psychedelics.
- Intense competition in the healthcare technology sector.
- Small number of employees.
What Could Drive EHVVF Stock Higher?
Potential regulatory approvals for medical psychedelics in key markets.
- Launch of new digital applications and therapeutic solutions.
- Expansion of strategic partnerships with healthcare providers and pharmaceutical companies.
- Increasing adoption of Ehave Dashboard by clinicians and healthcare organizations.
- Growing awareness of mental health issues and demand for innovative solutions.
What Are the Key Risks for EHVVF?
Financial-distress signal — its Altman Z-Score of -26.45 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles and changing healthcare policies.
- Technological obsolescence and cybersecurity risks.
- Economic downturn and reduced healthcare spending.
- Competition from larger and more established companies.
- Dependence on key personnel and strategic partnerships.
What Are the Growth Opportunities for EHVVF?
- Expansion of Product Offerings: EHAVE can expand its product offerings by developing new digital applications and therapeutic solutions tailored to specific mental health conditions. The market for specialized mental health apps is growing rapidly, with an estimated market size of $10 billion by 2028. By introducing innovative products that address unmet needs, EHAVE can attract new customers and increase its market share. This expansion can be achieved through internal development efforts, strategic acquisitions, or partnerships with other technology companies. The timeline for launching new products is estimated to be within the next 1-3 years.
- Strategic Partnerships: EHAVE can form strategic partnerships with healthcare providers, pharmaceutical companies, and research institutions to expand its reach and accelerate the adoption of its technology solutions. Collaborating with established players in the healthcare industry can provide EHAVE with access to new markets, distribution channels, and expertise. For example, partnering with a large hospital network could enable EHAVE to integrate its platform into the hospital's existing infrastructure, providing clinicians with seamless access to its tools. These partnerships can be established within the next 6-12 months.
- Regulatory Advancements in Medical Psychedelics: EHAVE can capitalize on regulatory advancements in the medical psychedelics space to develop and commercialize psychedelic-assisted therapies. As regulations surrounding psychedelics become more favorable, EHAVE can leverage its expertise in digital health and data analytics to create innovative treatment protocols and monitoring tools. The market for psychedelic-assisted therapies is projected to reach $5 billion by 2030. EHAVE can position itself as a leader in this emerging field by conducting clinical trials, obtaining regulatory approvals, and establishing partnerships with psychedelic research organizations. This opportunity is contingent on regulatory changes that are expected to occur over the next 3-5 years.
- Geographic Expansion: EHAVE can expand its geographic presence by entering new markets in North America and Europe. The demand for mental health solutions is growing globally, presenting significant opportunities for EHAVE to expand its customer base and increase its revenue. By adapting its platform to meet the specific needs of different markets, EHAVE can attract new customers and establish a strong foothold in key regions. The timeline for geographic expansion is estimated to be within the next 2-4 years, focusing on markets with favorable regulatory environments and high demand for mental health services.
- Data Monetization: EHAVE can explore opportunities to monetize its data assets by providing anonymized and aggregated data to pharmaceutical companies, research institutions, and other healthcare organizations. The market for healthcare data is growing rapidly, with an estimated market size of $25 billion by 2027. By leveraging its expertise in data analytics and blockchain technology, EHAVE can create valuable data products that address the needs of its customers. This can be achieved by establishing data sharing agreements, developing data analytics tools, and ensuring compliance with privacy regulations. The timeline for data monetization initiatives is estimated to be within the next 1-2 years.
What Are EHVVF's Competitive Advantages?
- Proprietary Technology: EHAVE's mental health data platform and digital applications are protected by patents and trade secrets.
- Data Network Effects: As more clinicians and patients use EHAVE's platform, the value of its data increases, creating a network effect.
- Strategic Partnerships: EHAVE's partnerships with healthcare providers and pharmaceutical companies provide access to new markets and expertise.
- First-Mover Advantage: EHAVE is an early mover in the emerging medical psychedelics and mental health technology space.
What Does EHVVF Do?
Incorporated in 2011 and based in Miami, Florida, EHAVE, Inc. operates as a healthcare technology company focused on developing medical psychedelics and a mental health data platform. The company's core mission revolves around integrating proprietary and third-party assessment and therapeutic digital applications to improve mental healthcare delivery in Canada. EHAVE offers a suite of technology solutions designed for various stakeholders, including clinicians, patients, researchers, pharmaceutical companies, and payors. Key products include MegaTeam and Ninja Reflex, clinically validated digital assessment and rehabilitation software designed to enhance patient engagement and data modeling. These tools are adapted from custom and third-party sources to provide comprehensive support. The Ehave Dashboard, a mental health informatics platform, allows clinicians to make objective and intelligent decisions through data insight using blockchain technology. This platform facilitates data-driven decision-making by providing clinicians with actionable insights derived from patient data. EHAVE also provides a platform for medical practitioners to administer healthcare services to patients at home, expanding access to care and improving patient outcomes. The company's solutions are designed to streamline workflows, improve data accuracy, and enhance the overall quality of mental healthcare services.
What Products and Services Does EHVVF Offer?
- Develops medical psychedelics and mental health data platforms.
- Integrates proprietary and third-party assessment and therapeutic digital applications.
- Offers MegaTeam and Ninja Reflex, clinically validated digital assessment and rehabilitation software.
- Adapts custom and third-party clinically validated digital assessment and rehabilitation software.
- Provides Ehave Dashboard, a mental health informatics platform using blockchain technology.
- Offers a platform for medical practitioners to administer healthcare services to patients at home.
- Provides technology solutions to clinicians, patients, researchers, pharmaceutical companies, and payors.
How Does EHVVF Make Money?
- Develops and licenses its proprietary mental health data platform and digital applications.
- Generates revenue through subscriptions and usage fees from clinicians, patients, and healthcare organizations.
- Partners with pharmaceutical companies and research institutions to provide data analytics and insights.
- Offers customized solutions and consulting services to meet the specific needs of its customers.
What Industry Does EHVVF Operate In?
EHAVE, Inc. operates within the rapidly evolving healthcare technology sector, specifically targeting the mental health market. The industry is experiencing significant growth driven by increasing awareness of mental health issues, technological advancements, and a shift towards personalized and data-driven care. Competitors include companies like ANDI, CAVR, CGUD, DFTC, and DVNCF, which are also developing digital health solutions. EHAVE's focus on integrating medical psychedelics and blockchain technology differentiates it within this competitive landscape.
Who Are EHVVF's Key Customers?
- Clinicians: Mental health professionals who use EHAVE's platform to assess and treat patients.
- Patients: Individuals seeking mental health support and utilizing EHAVE's digital applications.
- Researchers: Academic and clinical researchers who leverage EHAVE's data and tools for mental health studies.
- Pharmaceutical Companies: Companies developing and marketing mental health medications and therapies.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 119 days ago
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 45 |
| 2026-08-26 | 45 |
| 2026-08-29 | 45 |
| 2026-09-01 | 45 |
| 2026-09-04 | 45 |
| 2026-09-07 | 45 |
| 2026-09-10 | 45 |
What changed?
The score has stayed at 45.
Over the same 18 days the stock moved +77.8%.
Financial Health
EHAVE, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -26.45 places it in the distress zone, a signal of elevated financial risk.
Quarterly Financial Performance: EHAVE, Inc.
Revenue for EHAVE, Inc. came in at $1K during Q4 FY2025. The company recorded a net loss of $545K, with diluted EPS of $-0.00.
EHVVF Valuation & Market Position
With a $2.37M market cap, EHAVE, Inc. sits in the micro-cap segment of the market.
Key Financial Metrics
Return on equity for EHAVE, Inc. stands at 15.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -29.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -48.0%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
EHAVE, Inc. operates in the Software - Application industry within the Technology sector. It is headquartered in Miami, US. The company is led by CEO Benjamin Kaplan. EHVVF has traded publicly since 2016.
EHVVF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary mental health data platform and digital applications.
- Focus on integrating medical psychedelics and blockchain technology.
- Strategic partnerships with healthcare providers and pharmaceutical companies.
- Experienced management team with expertise in healthcare and technology.
Bear Case
- Limited financial resources and operating history.
- Dependence on regulatory approvals for medical psychedelics.
- Intense competition in the healthcare technology sector.
- Small number of employees.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 FY2025 | $1,092 | -$545,172 | -$0.0004 |
| Q3 FY2025 | $1,092 | -$545,172 | -$0.0004 |
Q4 FY2025 · filed 15 May 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
EHVVF Latest News
-
Ehave's Mycotopia Therapies To Merge With Ei.Ventures To Form PSLY.COM
benzinga · May 23, 2022
-
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
· Oct 18, 2021
-
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
· Oct 13, 2021
EHVVF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for EHVVF.
Price Targets
Wall Street price target analysis for EHVVF.
EHVVF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for EHVVF; grades run from A+ (80-100) to F (below 30).
Latest News
Ehave's Mycotopia Therapies To Merge With Ei.Ventures To Form PSLY.COM
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Leadership: Benjamin Kaplan
CEO
Benjamin Kaplan serves as the CEO of EHAVE, Inc. His background includes experience in managing early-stage companies and navigating the complexities of the healthcare technology sector. Kaplan's expertise lies in strategic planning, business development, and capital raising. He has a proven track record of building and scaling innovative companies in emerging markets. His leadership is focused on driving growth, fostering innovation, and creating value for shareholders.
Track Record: Under Benjamin Kaplan's leadership, EHAVE, Inc. has focused on developing its mental health data platform and expanding its product offerings. Key milestones include the launch of the Ehave Dashboard and the establishment of strategic partnerships with healthcare providers. Kaplan has also overseen the company's efforts to navigate the regulatory landscape for medical psychedelics and position EHAVE as a leader in this emerging field. Given the limited information available, a comprehensive assessment of his long-term track record is challenging.
EHVVF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that EHAVE, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, which can increase the risk of fraud and manipulation. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Limited Financial Disclosure: The unknown disclosure status makes it difficult to assess the company's financial health and performance.
- Low Liquidity: The stock may experience low trading volumes and wide bid-ask spreads, increasing transaction costs and price volatility.
- Regulatory Uncertainty: OTC stocks face fewer regulatory requirements, increasing the risk of fraud and manipulation.
- Speculative Nature: EHAVE, Inc.'s focus on medical psychedelics and mental health technology is highly speculative and subject to regulatory risks.
- Limited Operating History: The company has a limited operating history and may face challenges in scaling its business and achieving profitability.
- Verify the company's registration and compliance with regulatory requirements.
- Obtain and review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Research the company's legal and regulatory risks.
- Understand the company's capital structure and funding sources.
- Monitor news and developments related to the company and its industry.
- Focus on developing medical psychedelics and mental health data platforms.
- Integration of proprietary and third-party digital applications.
- Partnerships with healthcare providers and research institutions.
- Development of Ehave Dashboard, a mental health informatics platform using blockchain technology.
- Experienced management team with expertise in healthcare and technology.
What Investors Ask About EHAVE, Inc. (EHVVF) — Technology
Is EHVVF a good stock?
Stock Expert AI does not rate EHVVF buy, sell or hold. EHAVE, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about EHVVF stock?
There is currently no available analyst coverage for EHVVF stock. Given its OTC listing and small market capitalization, the stock is unlikely to be actively followed by major investment banks or research firms. Investors should conduct their own independent research and due diligence before investing in EHVVF.
What are the key factors to evaluate for EHVVF?
Evaluate EHVVF on fundamentals, analyst consensus, and risk factors. EHAVE, Inc. operates in the healthcare technology sector, focusing on medical psychedelics and mental health data platforms. Not financial advice.
How frequently does EHVVF data refresh on this page?
EHVVF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven EHVVF's recent stock price performance?
EHAVE, Inc. (EHVVF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary mental health data platform and digital applications. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EHVVF overvalued or undervalued right now?
EHAVE, Inc. (EHVVF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of EHVVF?
Yes, most major brokerages offer fractional shares of EHAVE, Inc. (EHVVF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track EHVVF's earnings and financial reports?
EHAVE, Inc. (EHVVF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for EHVVF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited due to the company's OTC status and lack of analyst coverage.
- Financial data is based on available information and may not be comprehensive.